Real-world (rw) treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic tx and avelumab 1L maintenance (1LM): Results from the IMPACT UC-III study.

Bibliographic Details
Published in:	Journal of Clinical Oncology Vol. 42; pp. 390 - 403
Main Authors:	Moon, Helen, Ike, Chiemeka, Morris, Valerie A., Wangia Dixon, Ruth, Tonnu-Mihara, Ivy, Crowe, Christopher L., Venkataraman, Malvika, Kearney, Mairead, Barron, John
Format:	Journal Article
Published:	American Society of Clinical Oncology 2024 Supplement 10
Online Access:	View this record in EBSCOhost

Internet